JPRN-jRCTs071180087已完成4 期
Comparative effect of daily teriparatide, weekly teriparatide, or bisphosphonate on bone microarchitecture in patients with primary osteoporosis: A HR-pQCT study. - TERABIT study
Osaki Makoto0 个研究点目标入组 131 人开始时间: 2019年3月29日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 131
研究概览
简要总结
We investigated the differences in the effects of daily teriparatide (20 micro g), weekly high-dose teriparatide (56.5 micro g), and bisphosphonate on postmenopausal osteoporosis patients with fragile fractures. D-PTH, W-PTH, and BPs were all shown to improve bone structure, although they exhibited different mechanisms and degrees of effects.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 <= 89age old（—）
- 性别
- Female
入选标准
- •1.Age: Patients over 60 years old and less than 89 years old.
- •2.Gender: female.
- •3.Inpatient or Outpatient: unmentioned.
- •4.Primary osteoporosis patients with one or more previous fragility fractures (e.g., proximal femoral fracture, vertebral fracture, distal radius fracture, proximal humerus fracture, rib fracture, pelvic fracture, lower leg fracture).
- •5.Medical history using Vitamin D preparation: unmentioned.
- •6.After receiving sufficient explanation for participation in this study, patients who gained written consent by the patient's free will with sufficient understanding.
排除标准
- •1.Patients with serious cardiac disorder, serious liver dysfunction, serious kidney dysfunction, diabetes mellitus, endocrine and metabolic diseases which may affect to the bone metabolism, and secondary osteoporosis (e.g., glucocorticoid-induced osteoporosis, rheumatoid arthritis, immobilization osteoporosis).
- •2.Patients treated with medication which affect to the bone metabolism as follows,
- •i)Glucocorticosteroids (within 6 months before enrollment, or >5mg for over 3 months) except inhaler or nasal drip.
- •ii)Anti-cancer drugs.
- •iii)Anti-osteoporosis drugs (teriparatide, anti-RANKL antibody, bisphosphonates within 6 months before enrollment, SERMs within 3 months before enrollment, or estrogen preparations).
- •3.Patients who have contraindication of teriparatide or bisphosphonate.
- •4.Patients who have severe allergy.
- •5.Patients enrolled in other clinical studies in the past 3 months.
- •6.Patients judged to be inadequate for this study by investigators.
研究者
相似试验
已完成
不适用
Comparative effect of daily teriparatide, weekly teriparatide, or bisphosphonate on bone microarchitecture in patients with primary osteoporosis: A HR-pQCT studyPrimary osteoporosisJPRN-UMIN000020584agasaki University Hospital130
已完成
4 期
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip FractureOsteoporosisNCT00887354Eli Lilly and Company224
已完成
3 期
Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced OsteoporosisOsteoporosisNCT00503399Eli Lilly and Company92
招募中
Unknown
Safety and efficacy of twice-weekly teriparatide in hemodialysis patients with osteoporosisChronic Kidney DiseaseJPRN-jRCTs011230047ishio Saori50
招募中
3 期
Effect of cinopar in mandibular fractureIRCT20180507039576N1Yazd University of Medical Sciences30